Clinical Trials Sponsored by Trio Grup Clinical Research

Total 342 results

Trio Grup Clinical Research

Unknown

Effectiveness And Safety of LMWH Treatment in Cancer Patients Diagnosed With Non-High Risk Venous Thromboembolism (TREBECA)

Venous Thromboembolism

Turkey
KM Clinical Research Group

Terminated

Change in Pain and Quality of Life Following SCS for Chronic Pain (BURST)

Pain, Radiating | Pain, Chronic | Pain Syndrome | Pain, Back

United States
KM Clinical Research Group

Withdrawn

Real-Time Accurate Pathology Inspection and Decompression Study (RAPID)

Radiculopathy | Pain, Chronic | Spine Injuries and Disorders | Pain, Back | Pain, Neck

United States
KM Clinical Research Group

Terminated

Quality of Life and Pain Changes Due to DRG Stimulation for Chronic Pain (ACTIVE)

Complex Regional Pain Syndromes | Pelvic Pain | Regional Pain Syndrome | Chronic Pain Syndrome | Spinal; Nerve Root, Pain

United States
Cardiology Clinical Research & Regulatory Group

Completed

Heat Retention Head Wrap Use for Re-warming of Infants Requiring Cardio-Pulmonary Bypass

Impaired Thermoregulation

United States
Tris Pharma, Inc.
Premier Research Group plc

Completed

Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD

ADHD

United States
Swiss Group for Clinical Cancer Research

Not yet recruiting

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

Triple-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Recruiting

LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma (SAKK 38/23)

Non-hodgkin Lymphoma, B Cell

Switzerland
Swiss Group for Clinical Cancer Research

Active, not recruiting

Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL

Leukemia | Chronic Lymphocytic Leukemia | Relapsed/Refractory Chronic Lymphocytic Leukemia

Switzerland
Swiss Group for Clinical Cancer Research

Terminated

ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.

Prostate Cancer | Prostate Cancer Metastatic

France, Switzerland, Spain, Italy
Swiss Group for Clinical Cancer Research

Completed

Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients

Lung Cancer

Germany, Serbia, Switzerland
Swiss Group for Clinical Cancer Research

Active, not recruiting

1st Line Durvalumab in PS 2 NSCLC Patients

NSCLC Stage IV | NSCLC Stage IIIB

Switzerland
Swiss Group for Clinical Cancer Research

Active, not recruiting

Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).

Small Cell Lung Cancer | Lung Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Active, not recruiting

Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. (SAKK 06/17)

Urothelial Cancer

Germany, Switzerland
Swiss Group for Clinical Cancer Research

Terminated

Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)

Squamous-cell Non-small Cell Lung Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Terminated

Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer

Adenocarcinoma | Breast Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.

Lung Cancer | KRAS Gene Mutation | Advanced Non-small Cell Lung Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Terminated

Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma (OptiPOM)

Refractory Multiple Myeloma

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Metformin Hydrochloride as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Prostate Cancer

Prostate Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Biological Therapy in Treating Patients With Bladder Cancer

Bladder Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumor

France, Switzerland, Germany, Finland
Swiss Group for Clinical Cancer Research

Completed

Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myeloproliferative Neoplasm

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer

Liver Cancer

Switzerland, Austria, Hungary
Swiss Group for Clinical Cancer Research

Completed

Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer

Breast Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma

Malignant Mesothelioma

Switzerland, Germany
Swiss Group for Clinical Cancer Research

Completed

Metronomic Therapy in Metastatic Breast Cancer.

Breast Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma

Lymphoma

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Combination Chemotherapy Followed by Radiation Therapy Before Surgery in Treating Patients With Stage IIIB NSCLC

Lung Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Liver Cancer

Switzerland, Netherlands
Swiss Group for Clinical Cancer Research

Completed

PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Lymphoma

Switzerland, Italy
Swiss Group for Clinical Cancer Research

Withdrawn

Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents

Prostate Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Lymphoma

France, Switzerland, Italy
Swiss Group for Clinical Cancer Research

Completed

Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Melanoma (Skin)

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Drugs to Reduce the Side Effects of Chemotherapy

Unspecified Adult Solid Tumor, Protocol Specific | Nausea and Vomiting

Switzerland, Italy
Swiss Group for Clinical Cancer Research

Completed

Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Cannot Be Removed By Surgery

Esophageal Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Neoadjuvant Docetaxel and Cisplatin Plus Chemoradiotherapy Followed By Surgery in Treating Patients With Locally Advanced, Resectable Esophageal Cancer

Esophageal Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

Colorectal Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Gemcitabine in Treating Patients With Newly Diagnosed, Relapsed, or Chemotherapy-Resistant Mantle Cell Lymphoma

Lymphoma

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer

Pain | Liver Cancer | Gallbladder Cancer | Extrahepatic Bile Duct Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Capecitabine and Vinorelbine in Treating Older Women Who Have Metastatic Breast Cancer With or Without Bone Involvement

Breast Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate Cancer

Prostate Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Chemotherapy in Treating Patients With Advanced Sarcoma

Sarcoma | Ovarian Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Combination Chemotherapy and Surgery in Treating Patients With Locally Advanced Stomach Cancer

Gastric Cancer

Switzerland, Italy
Swiss Group for Clinical Cancer Research

Completed

Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer

Breast Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Recruiting

Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

Bladder Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Recruiting

Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.

Diffuse Large B-cell Lymphoma

Switzerland, Italy
Swiss Group for Clinical Cancer Research

Recruiting

Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)

NSCLC | Non-small Cell Lung Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Recruiting

TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors

Advanced Solid Tumors

Switzerland

Clinical Trials Sponsored by Trio Grup Clinical Research

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations